Home > Insider Trading > Filing (0000947871-25-000309)

Filing Details

Accession Number:: 0000947871-25-000309
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-03-12 21:36:13
Reporting Period:: 2025-03-10

Filing Date:: 2025-03-12
Accepted Time:: 2025-03-12 21:36:13
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1816736	Disc Medicine Inc.	IRON	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1794070	Mona Ashiya	C/O Disc Medicine, Inc. 321 Arsenal Street, Suite 101 Watertown MA 02472		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-03-10	68,766	$54.29	539,845	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2025-03-10	106,384	$54.29	835,185	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2025-03-10	26,596	$54.29	208,795	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2025-03-10	136	$55.01	539,709	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2025-03-10	211	$55.01	834,974	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2025-03-10	53	$55.01	208,742	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2025-03-11	9,222	$54.01	530,487	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2025-03-11	14,267	$54.01	820,707	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2025-03-11	3,567	$54.01	205,175	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2025-03-12	603	$55.05	529,884	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2025-03-12	933	$55.05	819,774	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2025-03-12	233	$55.05	204,942	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2025-03-12	27,750	$54.44	502,134	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2025-03-12	42,930	$54.44	776,844	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2025-03-12	10,733	$54.44	194,209	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Footnotes

Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.66 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $55.01 to a high of $55.02 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.07 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $55.03 to a high of $55.11 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.96 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.
These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII, and OrbiMed is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.